Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bioo Scientific Launches a New Division, Bioo Therapeutics

Published: Thursday, November 12, 2009
Last Updated: Thursday, November 12, 2009
Bookmark and Share
Bioo Therapeutics will leverage Bioo Scientific’s proprietary drug delivery vehicles and antibody research expertise to develop therapeutic agents.

Bioo Therapeutics, a division of Bioo Scientific, was launched to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases.

Bioo Therapeutics flagship drug delivery technology is a patent pending antibody conjugation technology which delivers small RNA drugs into specifically targeted cells or tissues.

The scientists at Bioo Scientific have made significant strides in developing and using antibody-based agents for the directed delivery of short interfering RNAs by improving the loading capacity of antibody drug carriers and demonstrating their ability to successfully deliver small RNAs into tumors generated from cells expressing the cell surface target.

Drugs or toxins can be attached to monoclonal antibodies which target a specific cell type forming monoclonal antibody conjugates. These monoclonal antibody conjugates are used as homing devices to deliver these substances directly into targeted cells. This patent pending technology can revolutionize the delivery of siRNA and other RNAi agents, as well as, other more traditional drugs.

"Bioo Therapeutics is actively seeking to partner with pharmaceutical companies or venture capitalists to make possible the therapeutic potential of this technology. This effort will advance targeted drug delivery which is vitally important for the development of new cures and treatments of cancer," said Lance Ford, VP of Research and Business Development for Bioo Scientific. This research is being supported by funding in part through grants from the National Science Foundation (NSF), the National Institute of Allergy and Infectious Disease (NIAID) and clients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bioo Scientific Awarded $550K to Improve Single Cell Sequencing Technologies
The first grant, Sequencing of Epigenetic Modifications from Single Cells, will be used to further the development of single-cell methylome sequencing for use in a number of applications.
Monday, April 11, 2016
Bioo Scientific Granted Patent
Company has announced that the USPTO has issued U.S. patent for improving data quality and small RNA sequencing technology.
Wednesday, March 16, 2016
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
Thursday, November 26, 2015
Bioo Scientific Receives USDA Approval
Approval for using its ELISA to screen meat for ractopamine residues.
Thursday, September 03, 2015
Bioo Scientific Partners with the Icahn School of Medicine at Mount Sinai
Partnership to reduce ligation bias in next generation sequencing.
Saturday, February 14, 2015
Bioo Scientific and Icahn School of Medicine Partner
Bioo Scientific partners with the Icahn School of Medicine at Mount Sinai to reduce ligation bias in next generation sequencing.
Tuesday, February 10, 2015
Bioo Scientific Awarded $750,000 NSF Grant
Company awarded a National Science Foundation Phase II grant to continue development efforts to improve the accuracy of small RNA expression analysis.
Wednesday, November 26, 2014
Bioo Scientific Receives Presidential Award for Exports
Awards are the highest recognition any U.S. entity may receive for making a significant contribution to the expansion of U.S. exports.
Thursday, May 29, 2014
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
The funding allows Bioo Scientific to develop a quantitative technology to measure miRNA expression in living cells or tumor tissue.
Wednesday, December 08, 2010
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
Bioo Scientific announced today that it has been awarded a grant of $150,000 from the National Science Foundation to support its research for the biomolecular detection of microRNA.
Wednesday, December 08, 2010
Bioo Scientific Chooses Eureka Genomics as its Next-Generation Sequencing Provider
Bioo Scientific chose Eureka Genomics based on their extensive sequencing experience, quick turnaround times and strong bioinformatics support.
Thursday, August 19, 2010
NSF Funds Research Partnership Between Bioo Scientific and Mirna Therapeutics
The funding will support tumor regression and pharmacokinetic studies on targeted delivery of microRNAs.
Thursday, July 22, 2010
Small RNA Barcoding for Sample Multiplexing
AIR Barcoded Adapters, designed to work with Illumina Next-Generation Sequencers, provide flexibility in high-throughput sequencing applications.
Monday, January 25, 2010
Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi
Dr Premlata Shankar, Professor and Co-Director, Center of Excellence of Infectious Disease Research at Texas Tech University, who has developed RNAi-based treatment methods for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the targeted delivery of siRNA into T cells.
Tuesday, November 17, 2009
Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi In Vivo Delivery Technology
A $500,000 Phase II grant will help to develop kits and reagents based on the patent-pending Targeted Transport Technology.
Wednesday, July 29, 2009
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Nanoparticles Target, Transform Fat Tissue
Nanoparticles designed to target white fat and convert it to calorie-burning brown fat slowed weight gain in obese mice without affecting food intake. This proof-of-concept work could lead to new therapies to treat obesity.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!